Financhill
Sell
15

ALLK Quote, Financials, Valuation and Earnings

Last price:
$0.26
Seasonality move :
-9.89%
Day range:
$0.25 - $0.26
52-week range:
$0.23 - $1.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.29x
Volume:
451K
Avg. volume:
1.5M
1-year change:
-80.62%
Market cap:
$22.9M
Revenue:
--
EPS (TTM):
-$1.32

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALLK
Allakos
-- -$0.18 -- -62.96% $0.35
AKRO
Akero Therapeutics
-- -$1.12 -- -16.23% $77.64
BIIB
Biogen
$2.4B $3.36 -1.89% 33.96% $201.18
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
SAGE
Sage Therapeutics
$14.4M -$1.36 79.76% -43.33% $8.05
VNDA
Vanda Pharmaceuticals
$52.3M -- -4.9% -- $12.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALLK
Allakos
$0.25 $0.35 $22.9M -- $0.00 0% --
AKRO
Akero Therapeutics
$44.88 $77.64 $3.6B -- $0.00 0% --
BIIB
Biogen
$143.54 $201.18 $21B 12.83x $0.00 0% 2.17x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
SAGE
Sage Therapeutics
$8.02 $8.05 $493.1M -- $0.00 0% 11.82x
VNDA
Vanda Pharmaceuticals
$5.08 $12.67 $296.2M -- $0.00 0% 1.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALLK
Allakos
-- -4.402 -- --
AKRO
Akero Therapeutics
-- 3.401 -- --
BIIB
Biogen
27.36% 0.257 28.25% 0.77x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
SAGE
Sage Therapeutics
-- 0.494 -- 7.17x
VNDA
Vanda Pharmaceuticals
-- -0.270 -- 4.22x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALLK
Allakos
-- -$24.7M -- -- -- -$12.5M
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
BIIB
Biogen
$1.9B $450.6M 7.33% 10.33% 14.32% $694.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
SAGE
Sage Therapeutics
$11.3M -$80.3M -63.59% -63.59% -626.87% -$66.6M
VNDA
Vanda Pharmaceuticals
$50.6M -$10.3M -3.49% -3.49% -19.33% -$2M

Allakos vs. Competitors

  • Which has Higher Returns ALLK or AKRO?

    Akero Therapeutics has a net margin of -- compared to Allakos's net margin of --. Allakos's return on equity of -- beat Akero Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    AKRO
    Akero Therapeutics
    -- -$0.99 --
  • What do Analysts Say About ALLK or AKRO?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Akero Therapeutics has an analysts' consensus of $77.64 which suggests that it could grow by 72.99%. Given that Akero Therapeutics has higher upside potential than Allakos, analysts believe Akero Therapeutics is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    AKRO
    Akero Therapeutics
    9 0 0
  • Is ALLK or AKRO More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Akero Therapeutics has a beta of -0.193, suggesting its less volatile than the S&P 500 by 119.294%.

  • Which is a Better Dividend Stock ALLK or AKRO?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Akero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or AKRO?

    Allakos quarterly revenues are --, which are smaller than Akero Therapeutics quarterly revenues of --. Allakos's net income of $376K is higher than Akero Therapeutics's net income of -$70M. Notably, Allakos's price-to-earnings ratio is -- while Akero Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus -- for Akero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
  • Which has Higher Returns ALLK or BIIB?

    Biogen has a net margin of -- compared to Allakos's net margin of 10.87%. Allakos's return on equity of -- beat Biogen's return on equity of 10.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    BIIB
    Biogen
    76.23% $1.83 $23B
  • What do Analysts Say About ALLK or BIIB?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 40.16%. Given that Biogen has higher upside potential than Allakos, analysts believe Biogen is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    BIIB
    Biogen
    13 17 0
  • Is ALLK or BIIB More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

  • Which is a Better Dividend Stock ALLK or BIIB?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or BIIB?

    Allakos quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Allakos's net income of $376K is lower than Biogen's net income of $266.7M. Notably, Allakos's price-to-earnings ratio is -- while Biogen's PE ratio is 12.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 2.17x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    BIIB
    Biogen
    2.17x 12.83x $2.5B $266.7M
  • Which has Higher Returns ALLK or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -49.65%. Allakos's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ALLK or NBY?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Allakos has higher upside potential than NovaBay Pharmaceuticals, analysts believe Allakos is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ALLK or NBY More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock ALLK or NBY?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or NBY?

    Allakos quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Allakos's net income of $376K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Allakos's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns ALLK or SAGE?

    Sage Therapeutics has a net margin of -- compared to Allakos's net margin of -747.33%. Allakos's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    SAGE
    Sage Therapeutics
    88.38% -$1.56 $465.1M
  • What do Analysts Say About ALLK or SAGE?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 0.33%. Given that Allakos has higher upside potential than Sage Therapeutics, analysts believe Allakos is more attractive than Sage Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    SAGE
    Sage Therapeutics
    0 15 0
  • Is ALLK or SAGE More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

  • Which is a Better Dividend Stock ALLK or SAGE?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or SAGE?

    Allakos quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Allakos's net income of $376K is higher than Sage Therapeutics's net income of -$95.8M. Notably, Allakos's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 11.82x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    SAGE
    Sage Therapeutics
    11.82x -- $12.8M -$95.8M
  • Which has Higher Returns ALLK or VNDA?

    Vanda Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -9.24%. Allakos's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    VNDA
    Vanda Pharmaceuticals
    95.13% -$0.08 $538.5M
  • What do Analysts Say About ALLK or VNDA?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 149.34%. Given that Vanda Pharmaceuticals has higher upside potential than Allakos, analysts believe Vanda Pharmaceuticals is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    VNDA
    Vanda Pharmaceuticals
    1 1 0
  • Is ALLK or VNDA More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

  • Which is a Better Dividend Stock ALLK or VNDA?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or VNDA?

    Allakos quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Allakos's net income of $376K is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Allakos's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 1.49x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    VNDA
    Vanda Pharmaceuticals
    1.49x -- $53.2M -$4.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock